A First-in-Human Randomized, Double-blind, Placebo-controlled, Fed-fasted, Gender, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMT-28 in Healthy Subjects

Trial Profile

A First-in-Human Randomized, Double-blind, Placebo-controlled, Fed-fasted, Gender, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMT-28 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs OMT 28 (Primary)
  • Indications Atrial fibrillation; Myocardial infarction
  • Focus Adverse reactions; First in man
  • Sponsors OMEICOS Therapeutics
  • Most Recent Events

    • 26 Jul 2018 Status changed from recruiting to completed.
    • 16 Mar 2017 Planned patient no is 92 as per NCT record. Kept higher no as per MR.
    • 09 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top